Professional
Added to YB: 2024-03-01
Pitch date: 2024-02-02
CSTL [bullish]
Castle Biosciences, Inc.
+45.69%
current return
Author Info
No bio for this author
Company Info
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Market Cap
$1.1B
Pitch Price
$23.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
-74.27
P/E
-56.02
EV/Sales
2.49
Sector
Health Care Providers and Services
Category
growth
RiverPark/Next Century Growth Fund New Position: Castle Biosciences, Inc.
$CSTL: Divested due to M&A uncertainty; skin cancer tests growing, acquisitions now contributing well. Underpenetrated markets = sustained growth potential. Valuation compressed over 3yrs, now appealing. Strong balance sheet for growth & nearing 2025 CF breakeven.
Read full article (1 min)